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Microglial activation has been considered a crucial player in the pathological process
of multiple human neurodegenerative diseases. In some of these pathologies, such as
Amyotrophic Lateral Sclerosis or Multiple Sclerosis, the immune system and microglial
cells (as part of the cerebral immunity) play a central role. In other degenerative
processes, such as Alzheimer’s disease (AD), the role of microglia is far to be elucidated.
In this “mini-review” article, we briefly highlight our recent data comparing the microglial
response between amyloidogenic transgenic models, such as APP/PS1 and AD
patients. Since the AD pathology could display regional heterogeneity, we focus our
work at the hippocampal formation. In APP based models a prominent microglial
response is triggered around amyloid-beta (Aβ) plaques. These strongly activated
microglial cells could drive the AD pathology and, in consequence, could be implicated
in the neurodegenerative process observed in models. On the contrary, the microglial
response in human samples is, at least, partial or attenuated. This patent difference
could simply reflect the lower and probably slower Aβ production observed in human
hippocampal samples, in comparison with models, or could reflect the consequence
of a chronic long-standing microglial activation. Beside this differential response, we
also observed microglial degeneration in Braak V–VI individuals that, indeed, could
compromise their normal role of surveying the brain environment and respond to
the damage. This microglial degeneration, particularly relevant at the dentate gyrus,
might be mediated by the accumulation of toxic soluble phospho-tau species. The
consequences of this probably deficient immunological protection, observed in AD
patients, are unknown.
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INTRODUCTION
Alzheimer’s disease (AD) is characterized by complex molecular and cellular alterations,
including the development of extracellular amyloid-beta (Aβ) deposits, intracellular aggregated
phosphorylated tau, dystrophic neurites, loss of synapses and neurons, and a prominent gliosis.
The reactive gliosis involves alterations in morphology and function of microglia and astrocytes
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(for recent reviews Heneka et al., 2015; Heppner et al.,
2015; Calsolaro and Edison, 2016; Ransohoff, 2016; Cuello,
2017). In fact, the so-called neuroinflammative process is
certainly a critical factor in the pathogenesis of multiple
neurological disorders, such as inflammatory autoimmune
diseases (e.g., multiple sclerosis). This inflammatory response
is also clearly associated to the development of AD and
microglia have recently emerged as crucial players in the
pathogenesis of the sporadic forms (Heneka et al., 2015;
Calsolaro and Edison, 2016; Ransohoff, 2016; Sarlus and
Heneka, 2017) though it is still unclear whether a detrimental
or protective but insufficient function contributes to disease.
It has long been recognized that Aβ neuritic plaques are
surrounded by activated microglial cells that could contribute
to Aβ phagocytosis and/or compaction (Hickman et al., 2008;
Frenkel et al., 2013). In fact, chronic microglial activation
could improve the AD pathology reducing the Aβ levels
in APP-based models (Michaud et al., 2013). However, the
inflammatory response has also been associated with neurotoxic
detrimental effects mediated by the release of proinflammatory
cytokines/chemokines and neurotoxins (Kettenmann et al.,
2011; Heneka et al., 2015; Heppner et al., 2015; Calsolaro
and Edison, 2016). The implication of microglia in the AD
pathology is also reinforced by human genome-wide association
studies (GWAS). These GWAS analysis have identified multiple
polymorphisms associated with the microglial immune response
(Guerreiro et al., 2013; Cuyvers and Sleegers, 2016; Hansen
et al., 2018). Within the different AD-associated genes, the
microglial triggering receptor expressed in myeloid cells 2
(TREM2) gene seems to perform a pivotal role in the
AD-associated immune response (Ulrich et al., 2017; Yeh
et al., 2017; Hansen et al., 2018). TREM2 is a lipid and
lipoprotein sensor that, through its adapter molecule DAP12,
supports reactive microgliosis (Wang et al., 2015; Yeh et al.,
2016). Furthermore, it has been recently demonstrated that
TREM2, interacting with ApoE (the major genetic risk factor for
AD), regulates the transcriptional activation of microglial cells
(Krasemann et al., 2017). However, the role of TREM2-mediated
microglial activation, or even the function of the microglial
cells in the pathology of AD, is not elucidated (Ulrich et al.,
2017).
Concerning to AD patients, the neuroinflammatory response
is probably not exclusively detrimental or beneficial. An
excessive microglial reaction could indeed be detrimental for
the surrounding neurons or neuronal elements. However, the
contrary, a deficient microglial response could also induce
a similar detrimental effect on neurons. For instance, the
absence of microglial response due to null mutations in
TREM2 produces Nasu-Hakola disease, a rare neurodegenerative
disease (Dardiotis et al., 2017). Therefore, the implication of the
microglial response on the development of a neurodegenerative
disease, such as AD, could be due to either an excessive or, on
the contrary, a deficient microglial activation. In consequence,
restoring microglial function may be a therapeutic option for AD
treatment.
The achievement of effective therapies for AD requires
modeling very specific aspects of the human pathology in
the mouse models. Most of our knowledge about microglial
activation in AD is so far based in studies using APP-based
transgenic mice which robustly recapitulate the amyloid
pathology but fail to develop neurofibrillary pathology. The
failure of translating anti-inflammatory strategies into the
clinical practice could be explained by a complex and differential
glial response in AD models and patients. Here we provide
an overview of the microglial response in amyloidogenic
models and human post-mortem hippocampus with the
aim of developing more predictive valuable animal models
and gain success in clinical trials using neuroinflammatory
targets.
DECODING MICROGLIAL ACTIVATION IN
MOUSE MODELS AND HUMAN BRAINS
APP-based transgenic mice displayed a considerable and
progressive extracellular Aβ accumulation in hippocampus and
cerebral cortex (Sasaguri et al., 2017). We and others (Jimenez
et al., 2008; Heneka et al., 2015) have previously described
that this extensive Aβ accumulation was accompanied by
intense local microglial activation (see Figures 1A,B). More
recently, the molecular signature of the microglial activation
has been broadly studied using single-cell RNA-sequencing
(Keren-Shaul et al., 2017). Using this powerful approach, genes
associated to the microglial activation have been identified.
In fact, these studies have clearly probed that microglial cells
are activated and express a particular genetic program called
‘‘disease associated microglia (DAM)’’. This DAM program
includes the expression of multiple genes (such as Csf1, Clec7a,
Igf-1), and some others associated to AD, like TREM2 or ApoE.
The same active microglia down-regulate the ‘‘homeostatic’’
genes, such as Cx3cr1, P2ry12 or Tmem119 (Keren-Shaul
et al., 2017). To investigate the microglial activation in our
APP/PS1 model, we have directly determined the change in
expression of some of these DAM and homeostatic genes from
hippocampal samples. To briefly summarized our data, the
change in the expression of microglial genes was displayed
graphically as heat-maps (Figure 1A) by calculating the z-score
between controls (wild-type mice, WT) and APP/PS1 samples
(9- to 12-month-old; n = 10 per genotype). As expected,
the levels of all these genes classified as part of the DAM
program were noticeably and significantly (p < 0.05, t-test)
induced. Furthermore, these activated microglial cells were
located surrounding, and probably isolating, the Aβ plaques
(Figures 1B,b1,b2). Therefore, as proposed previously, this
microglial activation could exert a protective role in the
AD pathology (Jimenez et al., 2008; Yeh et al., 2016; Yuan
et al., 2016; Zhao et al., 2017). In this sense, it has been
proposed that DAMphenotype could be neuroprotective (Keren-
Shaul et al., 2017), although this role is actually under
debate.
Concerning to the homeostatic genes, we have determined
the expression of three of them, such as CX3CR1, P2ry12 and
Tmem119 (see Figure 1A). As shown, in the APP/PS1 model,
the expression of these particular genes was either not altered
(P2ry12, Tmem119) or exhibited a small but significant
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FIGURE 1 | Microglial activation in APP/PS1 and microglial pathology in Alzheimer’s disease (AD) hippocampus. (A) Differential expression of selected microglial
genes from hippocampus of 9- to 12-month-old APP/PS1 mice (age-matched wild-type (WT) as controls; n = 10 per genotype) and post-mortem human Braak V–VI
samples (n = 28; age-matched non-demented BraaK II individuals as controls, n = 21) determined by qPCR analysis. Data were graphically plotted as Z-score and
represented the deviation in the expression of a gene over the mean expression of this particular gene in the control populations (WT or Braak II). Each bar
represented an individual murine or human sample. High expression is marked by the red color spectrum, low expression by blue colors. (B) Immunohistochemical
detection of microglial cells around amyloid plaques in 12-month old APP/PS1 mice (b1,b2), human AD brains staged as Braak IV (b3,b4) or Braak V–VI (b5,b6).
Amyloid plaques are surrounded by abundant activated Iba1-positive (b1) and CD45-positive (b2) microglia in the transgenic mice. Human plaques also displayed
Iba1-positive and CD45-positive associated microglia at Braak IV stage, however the presence of amyloid deposits devoid of Iba1-positive microglia was often
present in the hippocampus of Braak V–VI cases. Asterisks indicate amyloid plaques. BV, blood vessel. Scale bars (b1–b4) 20 µm; (b) 200 µm; (b6) 50 µm.
(C,D) The Iba1-load quantitative analysis revealed a regional pattern with DG>CA3>CA1>parahippocampal gyrus (PHG) in Braak II (C,c1–4,D, green circles). In
Braak V–VI individuals a significant (p < 0.05, Mann Whitney test) reduction of the microglial load was evidenced in the DG and CA3 regions (D, orange squares).
(E) Compared to Braak II microglial cells (e1 shows a non-activated healthy Iba1-positive microglial cell), Braak V–VI cases exhibit microglial cells with degenerative
morphological features including deramification (e2), fragmentation (e3), beadings and spheroidal swellings (e4,e5) and dystrophies (e6) of the processes. h, hilar
region; g, granular layer; m, molecular layer; so, stratum oriens; sp, stratum pyramidale; sl, stratum lucidum; sr, stratum radiatum. Scale bars, (c1–8) 100 µm;
(e1–6) 20 µm. (F) Differential accumulation of soluble Aβ and phospho-tau forms in the hippocampus of human Braak II and Braak V–VI brains. Quantitative data
from dot blots or western blots of soluble S1 fractions (extracellular/cytosolic) isolated from Braak II (n = 8) or Braak V–VI (n = 8) individuals. The relative abundance
(Continued)
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FIGURE 1 | Continued
of A11 or OC positive Abeta oligomers, AT8 or AT100 phospho-tau proteins
was determined by densitometry analysis. Significance was determined by
Mann Whitney test. (G) Soluble phospho-tau toxicity on BV2 microglial cells.
Microglia were incubated with S1 fractions isolated from Braak II, V–VI
samples or 18-month-old APP/PS1 or 12-month-old Thy1-tau22 models. The
toxicity was analyzed by flow cytometry and the percent of viable cells was
showed. The Aβ or phospho-tau was immunodepleted from the Braak V–VI
S1 fractions using 6E10 plus 82E1 or AT8 plus AT100 antibodies, respectively.
The data are shown as the mean ± SD of six different experiments.
Significance (indicated in the figure) was determined by ANOVA and Tukey
post hoc test. Data were taken from Jimenez et al. (2008, 2014);
Moreno-Gonzalez et al. (2009); Sanchez-Mejias et al. (2016); Baglietto-Vargas
et al. (2017) and Gutierrez and Vitorica (2018).
(p < 0.05) increase (CX3CR1), compared with age-matched
WT mice. As mentioned above, since the expression of
these particular genes decreased upon ‘‘activation’’ (Keren-
Shaul et al., 2017; Krasemann et al., 2017) these data were
somehow conflictive. In fact, we have corroborated by in vitro
experiments using primary microglial cells the decrease in
these homeostatic genes after stimulation with either LPS or
oligomeric Aβ (oAβ). Thus, the increase observed in some of
these homeostatic genes could also reflect the proliferation of
microglial cells in these models (Baglietto-Vargas et al., 2017).
Microglia are self-renewal cells that, upon activation, could
proliferate to develop an immune response (Askew et al., 2017;
Tay et al., 2017). In fact, we also observed an increase in the
expression of the mitotic marker Ki67 paralleled by increase
in the BrdU incorporation on microglial cells (Baglietto-Vargas
et al., 2017). Similarly, Füger et al. (2017) have reported a
three-fold increase of the microglial proliferation in a different
APP/PS1 model.
On the other hand, it has been classically assumed that
the microglial response in AD patients could be similar to
that observed in the amyloidogenic transgenic mice. Thus,
we have also analyzed the microglial response in human
hippocampus from non-demented Braak II controls (n = 21)
and age-matched AD cases staged as Braak V–VI (n = 28).
The expression of the different genes was calculated as z-score
and showed individually in the graph (Figure 1A). Using
this graphic approach, it is clear that the microglial reaction
in AD samples differs obviously from that observed in the
amyloidogenic model. An attenuated, rather than amplified,
microglial response, was identified in the hippocampus of
AD patients. As shown in Figure 1A, only few DAM
genes were significantly (Mann Whitney test, p < 0.05)
induced, such as CD45, CD68 and Csf1 in Braak V–VI
samples, as compared with age-matched control individuals.
Furthermore, this induction was clearly weakened as compared
with APP/PS1 models. The apparently incomplete-activated
microglial cells were principally surrounding the extracellular
amyloid deposits (Figures 1B,b3,b4). On the other hand, the
expression of homeostatic genes, such as Cx3cr1 and P2ry12,
seemed to be significantly decreased in AD patients. We do not
know whether this decrease in the expression reflects the partial
microglial activation or, on the contrary, reflects a change in the
microglial number.
Although microglial activation has been observed in cerebral
regions with early and abundant extracellular Aβ deposits
(Serrano-Pozo et al., 2013; Hamelin et al., 2016), our data
clearly show that the microglial activation observed in the
hippocampus of APP-based models undoubtedly differs both
qualitative and quantitative from that observed in AD patients.
This clear difference could reflect a different kinetic and/or
magnitude of the Aβ accumulation. It is possible that the
microglial response to the fast and extensive Aβ accumulation
in transgenic models may resemble an acute response rather
than a chronic and insidious pathology as observed in patients.
On the other hand, and restricted to human samples, in Braak
V–VI hippocampus we also observed neuritic plaques not
surrounded by Iba1-positive microglial cells (Figures 1B,b5,b6).
These ‘‘nude’’ amyloid plaques were not diffuse unreactive
plaques. Thus, these data demonstrated the existence of
substantial differences in the microglial response between
APP-models and AD cases, at least at the hippocampal
formation.
MICROGLIAL DETERIORATION IN THE
HIPPOCAMPUS OF AD PATIENTS
As we pointed above, the microglial response in AD
samples is quite dissimilar from that observed in APP-
models. Furthermore, the existence of Aβ plaques with no
surrounding/isolating Iba1-positive microglia led us to speculate
with the existence of a pathological microglial process in
AD patients. Thus, we analyzed using immunohistochemical
staining the microglial response in AD cases (Braak V–VI)
compared to controls (Braak II; Figure 1C). Using these
experimental approaches, we first realized the existence
of a regional microglial compartmentalization within the
hippocampal formation. In Braak II control samples the
parenchymal distribution of microglia cells, determined as Iba1-
load, was significantly higher at the hilar region and CA3 than
in CA1 or parahippocampal gyrus (PHG; Figures 1C,c1–4,D,
green circles). The reasons and implications of this particular
heterogeneity were actually unknown; however, it could
reflect a different role or different immune-requirements
associated to the particular connections between DG and
CA3 regions. On the other hand (Figures 1C,c5–8,D), there
was a clear and consistent (seven out of eight individuals
tested) reduction in the microglial load (Iba1-immunopositive
area) in Braak V–VI hippocampus. This reduction was
not homogeneous for all regions analyzed. In fact, it was
restricted to the hilar region of the DG and the CA3 subfield
of the hippocampal formation. Other regions, such as
CA1 and PHG were less affected, or unaffected, in the
Braak V–VI samples. These data could indicate the existence
of a possible microglial degenerative process restricted to
DG and CA3 subfields. Thus, we focused our attention
on the hilar region of the DG and further analyzed this
putative microglial degeneration by determining: (1) the
numerical density (cells/mm3) of Iba1-positive cells; (2) the
parenchymal area covered by each microglial cell (microglial
domain); and (3) the spatial distribution pattern of microglia
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(spatial covered). Interestingly, the numerical density of
Iba1-positive cells was reduced in approximately 50% of
the AD cases (Sanchez-Mejias et al., 2016). On the other
hand, all tested samples showed clear modifications of
the microglial morphology (Figures 1C,c1–4). In Braak II
samples, microglial cells displayed a healthy morphology with
highly ramified processes and were arranged with a regular
spatial distribution covering, and probably protecting, most
parenchymal space. This scenario was totally different in
pathological Braak V–VI individuals. We observed a high
and consistent reduction in both the microglial domain
(area of surveillance of an individual cell) and in the spatial
coverage of the hilar region of the DG (Sanchez-Mejias et al.,
2016). In consequence, in AD hippocampus most of the
parenchymal space of the hilar region was devoid on microglial
protection.
This decrease was due to the existence of a clear pathological
morphology of the microglial cells. As mentioned above, in
Braak II samples, microglia showed a healthy morphology
(Figures 1E,e1). On the contrary, Braak V–VI microglial
cells displayed a shortened and less branched processes that
usually were deformed, displaying cytoplasmic abnormalities
(including spheroids) and even fragmentation (cytorrhexis;
Figures 1E,e2–6). This microglial pathology in AD and even
in Down syndrome brains has been previously reported (Lopes
et al., 2008; Streit et al., 2009, 2014; Xue and Streit, 2011),
however, it has never been detected in APP-based models
(Figure 1; Jimenez et al., 2008; Heneka et al., 2015). This
remarkable discrepancy between models and patients could
also explain the patent differences in the expression of
the DAM phenotype markers. As also mentioned, we also
noted the existence of amyloid plaques without surrounding
Iba1-positive microglial cells. If the microglial activation
around Aβ plaques were indeed protective and constituted a
preventive response by compacting plaques and isolating the
putative toxic Aβ oligomers from the neuronal environment
(Yuan et al., 2016), the existence of ‘‘nude’’ Aβ plaques
in AD hippocampus could indeed increase the toxicity of
these extracellular aggregates and drive neuronal damage and
death.
SOLUBLE PHOSPHO-TAU IS
RESPONSIBLE FOR THE MICROGLIAL
DEGENERATION IN AD BRAINS
So far, we have demonstrated the existence of an evident
pathological process in AD hippocampus affecting the microglial
cells. To address which was the potential microglial toxic
factor(s) in AD brains we examined whether soluble factors,
such as oAβ or phosphorylated tau (phospho-tau) in Braak
V–VI samples were the toxic agents (Sanchez-Mejias et al.,
2016). In this sense, our previous work demonstrated that
the hippocampus of APP-based models accumulated, in an
age-dependent mode, soluble oAβ (Torres et al., 2012; Trujillo-
Estrada et al., 2013; Jimenez et al., 2014). These soluble
oAβ increased in aged APP-models and induced microglial
activation in the inter-plaque areas (Jimenez et al., 2008).
However, though the soluble oAβ also increased in Braak
V–VI samples (tested using A11 or OC antibodies in dot-
blots, Figure 1F), these oligomeric species were very scarce in
Braak V–VI hippocampus (Jimenez et al., 2014). This apparent
contradiction could be explained by the distinct development of
AD pathology (lesions, course) between amyloidogenic models
and AD samples. Models presented a high extracellular Aβ
accumulation in both cortical areas and hippocampal complex
since early ages (Trujillo-Estrada et al., 2014). However, human
AD hippocampus, along with the entorhinal cortex, is one of
the first regions to be affected by tau pathology and only,
in very advanced stages, amyloid plaques are also present.
In fact, the soluble fractions extracted from Braak V–VI
hippocampus displayed relatively high content in AT100 and
AT8 positive phospho-tau (Figure 1F) and relatively low oAβ
levels.
We tested in vitro, using Bv2 cells or primary microglial
cultures, whether soluble fractions (S1) derived from AD
hippocampus were toxic (Figure 1G). The S1 fractions form
Braak V–VI samples produced a clear reduction on the
number of viable microglia, either Bv2 or primary cultures.
This toxic effect was avoided by immunodepletion using
a combination of AT8 plus AT100 antibodies whereas the
same approach using 6E10 plus 82E1 monoclonal antibodies
for Aβ produced absolutely no effect (Figure 1G). Thus,
soluble phospho-tau seemed to be toxic for microglial cells
in vitro. We further confirmed these results using soluble
fractions extracted from aged APP/PS1 (18-month-old) or
Thy-Tau22 (12-month-old) models. As expected, S1 fractions
enriched in Aβ (APP/PS1; Jimenez et al., 2008) produced
no effect whereas those containing phospho-tau (tau22)
were toxic (Figure 1G). All these data demonstrated that,
at least in vitro, soluble phospho-tau reduced the viability
of microglial cells. This hypothesis was also supported by
in vivo colocalization of dystrophic microglial cells with
phospho-tau positive neuronal structures (Sanchez-Mejias et al.,
2016).
In sum, our work highlights relevant differences in the
hippocampal inflammatory response between APP-transgenic
mice and AD patients regarding microglial gene expression,
morphology and survival (see Figure 2). In APP-models,
the high and probably fast accumulation of extracellular
Aβ produces a prominent microglial response. The activated
microglial cells are predominantly located surrounding Aβ
plaques, although active microglia are also identified in inter-
plaque regions. While the role of the activated microglia
could be neuroprotective, the strong microglial activation in
APP models could also drive the AD pathology (Maphis
et al., 2015; Olmos-Alonso et al., 2016; Spangenberg et al.,
2016) and, in consequence, it could be implicated in the
neurodegenerative process observed in APP-models. On the
contrary, the microglial response in AD hippocampus is
really mild. This patent difference could simple reflect the
lower and probably slower Aβ production observed in human
hippocampal samples, in comparison with models. However,
and more relevant, in Braak V–VI samples there is a prominent
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FIGURE 2 | Dissimilar progressions of hippocampal microglial response in APP/PS1 mice and human brains. (A) Illustrate the age-dependent microglial activation in
the amyloidogenic model from 4 (left) to 12 (right) months of age. Activated microglia characterized by morphological changes (hypertrophy of cell body and
shortened processes) selectively cluster around amyloid plaques at early ages. Increased amyloid load with age is associated with expansion of the microglial
activation. The age-dependent accumulation of soluble Aβ oligomers induces the activation of the interplaque microglia in aged transgenic mice. (B) Illustrate the
microglial response during the course of AD pathology in the hippocampus of human brains. Amyloid pathology is a late event in the hippocampus while tau
pathology shows a very early onset. In Braak III–IV hippocampus, some amyloid plaques are present and they are surrounded by activated microglia, however in late
stage AD (Braak V–VI) microglial-bare plaques are usually found. The high content of phospho-tau forms (intra- and/or extracellular) induces the degeneration of
microglial cells in human Braak V–VI hippocampus.
microglial degenerative process that, indeed, could compromise
their normal role of surveying the brain environment and
respond to the damage. This microglial pathology, particularly
relevant at the dentate gyrus of the hippocampal formation,
might be mediated by the accumulation of toxic soluble
phospho-tau species. The consequences of this probably deficient
immunological protection due to the microglial degeneration,
observed in AD patients, are unknown. Considering that
microglial cells are implicated in multiple beneficial functions,
such as Aβ phagocytosis, senile plaque compaction and
limitation of Aβ toxicity and eliminating damaged neuron
or neuronal debris (Yeh et al., 2016; Yuan et al., 2016;
Ulland et al., 2017), a deficient microglial response could
indeed aggravate the progression of AD pathology. In this
sense, deficiencies on key genes for the microglial survival
and/or proliferation (such as CSF1R or TREM2) are associated
with rare hereditary neurodegenerative diseases, such as
adult-onset leukoencephalopathy with axonal spheroids or
Nasu-Hakola disease (respectively) (Paloneva et al., 2000,
2002; Chitu et al., 2016). In both diseases, the microglial
response and, more relevant, the microglial survival seems
to be compromised (Nataf et al., 2005; Satoh et al., 2011;
Konno et al., 2014; Tada et al., 2016). On the other hand,
missense mutations in TREM2 (such as R47H TREM2) produce
an increases risk for late-onset AD (Guerreiro et al., 2013;
Korvatska et al., 2015; Yeh et al., 2016) and a reduction
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in the number of microglial cells surrounding Aβ plaques
in models. This decrease produced less compact and higher
toxic plaques (Yeh et al., 2016; Yuan et al., 2016; Ulland
et al., 2017). Therefore, a deficient rather than an exacerbated
microglial response could be implicated in the development of
sporadic AD.
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